TY - CHAP M1 - Book, Section TI - Drug-Induced Liver Disease A1 - Kirchain, William R. A1 - Allen, Rondall E. A2 - DiPiro, Joseph T. A2 - Talbert, Robert L. A2 - Yee, Gary C. A2 - Matzke, Gary R. A2 - Wells, Barbara G. A2 - Posey, L. Michael Y1 - 2017 N1 - T2 - Pharmacotherapy: A Pathophysiologic Approach, 10e AB - KEY CONCEPTS Through its normally functioning enzymes and processes the liver often causes a drug to become toxic through a process known as bioactivation. Drug-induced liver disease (DILD) can have many different clinical presentations: idiosyncratic reactions, allergic hepatitis, toxic hepatitis, chronic active toxic hepatitis, toxic cirrhosis, and liver vascular disorders. The mechanisms of DILD are diverse, representing many phases of biotransformation, and are susceptible to genetic polymorphism. The assessment of a possible liver injury caused by drugs should include what is known in the literature, the timing involved, the clinical course, and, always, an exploration for preexisting conditions that may have encouraged the lesion’s development. Liver enzyme assays in serum can help to determine if a particular type of liver damage is present. Monitoring for DILD must be tailored to the drug and the patient’s potential risk factors. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1145220291 ER -